Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Magle Chemoswed Holding AB (OSTO:MAGLE) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Magle Chemoswed Holding AB Equity-to-Asset Related Terms
Magle Chemoswed Holding AB Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:MAGLE vs VRTX, REGN, MRNA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Magle Chemoswed Holding AB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Magle Chemoswed Holding AB Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Magle Chemoswed Holding AB's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Magle Chemoswed Holding AB's Equity-to-Asset falls into.
Magle Chemoswed Holding AB Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Magle Chemoswed Holding AB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Magle Chemoswed Holding AB (OSTO:MAGLE) has a Equity-to-Asset of 0.32 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Magle Chemoswed Holding AB and its competitors. This is 44% below median its historical median of 0.57. Over the past decade, Magle Chemoswed Holding AB's Equity-to-Asset has ranged from 0.32 to 0.66. According to the industry distribution chart, Magle Chemoswed Holding AB ranks #1100 out of 1414 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Magle Chemoswed Holding AB's Equity-to-Asset too high?
Magle Chemoswed Holding AB's current Equity-to-Asset of 0.32 is 44% below median its 10-year median of 0.57. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 0.66. The Biotechnology industry median Equity-to-Asset is 0.68. Magle Chemoswed Holding AB's value of 0.32 is 52.9% below this industry median. Based on the distribution chart, Magle Chemoswed Holding AB ranks #1100 out of 1414 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Magle Chemoswed Holding AB has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Magle Chemoswed Holding AB's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Magle Chemoswed Holding AB ranks #1100 out of 1414 companies for Equity-to-Asset. This places Magle Chemoswed Holding AB in the lower half of its industry. The industry median Equity-to-Asset is 0.68. Magle Chemoswed Holding AB's value of 0.32 is 52.9% below this benchmark. Historically, Magle Chemoswed Holding AB's own Equity-to-Asset has ranged from 0.32 to 0.66 over the past decade. While the company's 10-year median is 0.57 vs. the industry median of 0.68, Magle Chemoswed Holding AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,414 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Magle Chemoswed Holding AB's current Equity-to-Asset of 0.32 is 52.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Magle Chemoswed Holding AB and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Magle Chemoswed Holding AB's current Equity-to-Asset is 0.32, which is 44% below median its own 10-year median of 0.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Magle Chemoswed Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Magle Chemoswed Holding AB (OSTO:MAGLE) is currently considered Possible Value Trap. The stock's GF Value™ is kr23.43, compared to a current price of kr0.40 — trading 98.3% below its estimated fair value. The current Equity-to-Asset is 0.32, which is 44% below median its 10-year median of 0.57 and 52.9% below the Biotechnology industry median of 0.68. Magle Chemoswed Holding AB's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Magle Chemoswed Holding AB (OSTO:MAGLE), the current Equity-to-Asset is 0.32 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Magle Chemoswed Holding AB (OSTO:MAGLE) Overvalued in 2026?
Based on GuruFocus' analysis, Magle Chemoswed Holding AB stock appears to be undervalued.
The current stock price of kr0.40 is trading 98.3% below its estimated GF Value™ of kr23.43.
GuruFocus considers Magle Chemoswed Holding AB to be Possible Value Trap.
Key valuation signals for OSTO:MAGLE:
Equity-to-Asset: 0.32 (44% below median its 10-year median of 0.57)
GF Value™: kr23.43 vs. price of kr0.40 (98.3% below fair value)
Industry Position: 52.9% below the Biotechnology median (#1100 of 1414)
No single metric tells the full story. See the OSTO:MAGLE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Magle Chemoswed Holding AB is a contract development and manufacturing organization that serves companies in the pharmaceutical and medical device industry on a contract basis. It provides comprehensive services from product development through product manufacturing. The company's products portfolio includes Warfarin sodium, Melperone hydrochloride, Isradipine, Amantadine sulfate, and Benserazide hydrochloride.
39GF Score
Get the complete analysis for OSTO:MAGLE
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:MAGLE has been successfully added to your 
